▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Todd Campbell

tmfebcapital

@ebcapital

Todd has been helping buy side portfolio managers as an independent researcher for over a decade. In 2003, Todd founded E.B. Capital Markets, LLC, a research firm providing action oriented ideas to professional investors. Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn.

Recent Articles by Todd Campbell

Oct 6, 2014 by Todd Campbell

Johnson & Johnson Takes Aim at Gilead Sciences, inc.

Johnson & Johnson's acquisition of Alios could pose a threat to Gilead Sciences' Hovaldi, but not for years.

Oct 6, 2014 by Todd Campbell

Balance Sheet Analysis on Rite Aid Stock

Does Rite Aid's balance sheet suggest the pharmacy chain is a buy or a sell?

Oct 5, 2014 by Todd Campbell

Acting Like Derek Jeter Can Make You a Better Investor

Derek Jeter is one of baseball's best players, but its not just little leaguers that can learn a thing or two from his career. Investors would be wise to pay attention too.

Oct 5, 2014 by Todd Campbell

A Cure for Ebola? These 3 Biotech Companies Are Working on It

Here's what you need to know about Ebola and the three companies arguably closest to developing a cure.

Oct 5, 2014 by Todd Campbell

Legalese Puts Obamacare in Jeopardy

An federal judge in Oklahoma has determined that Affordable Care Act subsidies can't be provided to people signing up for coverage through healthcare.gov, but the decision may not stand.

Oct 5, 2014 by Todd Campbell

Gilead Sciences' Other Important New Drug

Gilead Sciences' Harvoni is getting all the press, but new HIV drug TAF could have a big impact, too.

Oct 5, 2014 by Todd Campbell

Why Johnson & Johnson, Bristol-Myers Squibb, and Pfizer Care So Much About This Tiny Biotech Company

Johnson & Johnson, Bristol-Myers Squibb, and Pfizer could see sales of their factor Xa drugs Xarelto and Eliquis jump if Portola Pharmaceuticals antidote succeeds in trials.

Oct 4, 2014 by Todd Campbell

The Biggest Threat Facing Johnson & Johnson

Three Motley Fool analysts debate the biggest risk facing Johnson & Johnson

Oct 4, 2014 by Todd Campbell

Humana Inc. Embraces Apple Health for Millions of Members

Insurers like Humana are encouraging members to live healthier lifestyles by rewarding members who use Apple devices to track their health.

Oct 3, 2014 by Todd Campbell

3 Steps to a Golden Retirement

Preparing for retirement can seem daunting, but these three steps may help you reach your retirement goals.

Oct 1, 2014 by Todd Campbell

Did Achillion Pharmaceuticals, Inc. Get Left Out in the M&A Cold?

Speculation that Achillion could be a takeover target was dampened following Johnson & Johnson's acquisition of Alios this week.

Oct 1, 2014 by Todd Campbell

Round 2 of Gilead Sciences, Inc.'s Offensive Begins

A key European advisory panel recommends Gilead's Harvoni for EU approval.

Sep 30, 2014 by Todd Campbell

Walgreen Company Earnings: Baby Boomers Drive Results Higher

Walgreen Company's sales and earnings grew in the past year as more Americans signed up for Medicare Part D plans.

Sep 29, 2014 by Todd Campbell

Gilead Sciences, Inc. Takes Aim at Bristol-Myers Squibb

Gilead Sciences has filed for approval of its next generation hepatitis C drug in Japan in a move that will challenge Bristol-Myers first to market advantage.

Sep 28, 2014 by Todd Campbell

7 Things Peyton Manning Can Teach Us About Investing

Peyton Manning's net worth is north of $100 million, so could lessons he's learned playing in the NFL help investors become wealthy, too?

Sep 28, 2014 by Todd Campbell

Is Medicare Costing You More?

Medicare parts B and D include premium adjustments that increase their cost to high income earners, but if seniors income changes the adjustment can be removed.

Sep 28, 2014 by Todd Campbell

The Insurers Obamacare Really Helps May Surprise You

Its private Medicaid insurers like Molina, not national insurers like UniteHealth Group, that are seeing the biggest jump in profits thanks to the Affordable Care Act.

Sep 27, 2014 by Todd Campbell

1 Marijuana Stock You Can Buy Right Now

While many medical marijuana stocks are trading at jaw-dropping valuations, Insys may be a relative value given the potential approval of its synthetic THC drug, dronabinol.

Sep 27, 2014 by Todd Campbell

Warren Buffett's $90 Million Bet on Risk

Warren Buffett loves risk, assuming of course that he can identify and price it. That's likely why he remains a fan of this risk analytics company.

Sep 26, 2014 by Todd Campbell

Is It Finally Time to Buy Dividend Stock GlaxoSmithKline plc?

GlaxoSmithKline has been stumbling because of patent expiration and sliding sales for its top-selling asthma drug, Advair, but that may not mean it's time to buy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services